Compare SEDG & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEDG | ENOV |
|---|---|---|
| Founded | 2006 | 1995 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Fluid Controls |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 2015 | 2008 |
| Metric | SEDG | ENOV |
|---|---|---|
| Price | $35.53 | $21.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 20 | 8 |
| Target Price | $26.86 | ★ $48.13 |
| AVG Volume (30 Days) | ★ 2.6M | 1.1M |
| Earning Date | 02-18-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,045,303,000.00 | ★ $2,233,266,000.00 |
| Revenue This Year | $33.45 | $9.18 |
| Revenue Next Year | $15.38 | $4.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 2.35 | ★ 11.57 |
| 52 Week Low | $11.00 | $21.00 |
| 52 Week High | $48.60 | $44.76 |
| Indicator | SEDG | ENOV |
|---|---|---|
| Relative Strength Index (RSI) | 54.78 | 39.14 |
| Support Level | $33.51 | $21.62 |
| Resistance Level | $37.85 | $23.18 |
| Average True Range (ATR) | 2.62 | 1.20 |
| MACD | 0.13 | 0.14 |
| Stochastic Oscillator | 72.45 | 29.96 |
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers.
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.